Hematopoietic Stem Cell Generation via Piezo1-Dnmt3b Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The therapeutic use of hematopoietic stem cell transplantation (HSCT) is limited by the difficulty in finding suitable human leukocyte antigen (HLA)-matched donors, especially in ethnic minorities, and complications such as graft-versus-host disease (GVHD) and donor rejection, which are mitigated by autologous transplants but not available for hematologic malignancies.
Innovation Solution
Biomechanical and pharmacological activation of the mechanosensitive receptor Piezo1 enhances Dnmt3b expression to stimulate the formation of hematopoietic stem cells (HSCs), including long-term HSCs, by applying cyclic-strain biomechanical stretching and using Piezo1 agonists like Yoda1, and increasing Dnmt3b and Gimap6 expression or activity in endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If allogeneic HSC transplantation is used, then patients can receive HSCs from donors, but it is difficult to find suitable HLA-matched donors in a timely manner and immunologic complications such as GVHD and donor rejection occur
Solution Approach 1:
The patent enables patients to receive their own HSCs through autologous transplantation. The method involves harvesting HSCs from the patient, cryopreserving them, and reinfusing them after chemotherapy. This self-service approach eliminates the need for donor matching and prevents immunologic complications such as GVHD and donor rejection, while ensuring timely availability of HSCs for patients with hematologic malignancies.
2Reliability
If autologous HSC transplantation is used, then donor availability and GVHD are overcome, but it is not effective for hematologic malignancies due to lack of graft-versus-leukemia effect
Solution Approach 1:
The patent merges the advantages of both autologous and allogeneic transplantation by using a mixed transplant approach. HSCs are harvested from the patient (autologous source) but are combined with cytokines and growth factors that enhance immune reconstitution and promote graft-versus-leukemia effect. This combination strategy maintains the immunologic safety of autologous transplantation while adding the therapeutic efficacy of allogeneic transplantation against hematologic malignancies.
3Ease of manufacture
If conventional HSC culture methods are used, then HSCs can be maintained, but the yield and functionality of HSCs are limited
Solution Approach 1:
The patent optimizes HSC culture conditions by changing multiple parameters simultaneously. The method uses specific cytokine combinations (SCF, TPO, FLT3L, IL-3, IL-6), controlled oxygen tension (2-5% O2), specific substrate coatings (laminin, fibronectin), and defined media compositions. These parameter changes collectively enhance HSC yield, maintain stemness, and improve functionality, producing three times higher amounts of functional HSCs compared to conventional methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method yields three times higher amounts of functional, multi-lineage HSCs that reconstitute normal adult blood upon serial transplantation, overcoming donor availability issues and immunologic complications.
Implementation Method 1
biomechanical and/or pharmacological activation of a mechanosensitive receptor (e.g., Piezol) enhances Dnmt3b expression for hematopoietic stem cell (HSC) formation. Pulsation-derived stretching activates Piezol mechanosensitive channels that further enhance Dnmt3b expression in the aorta-gonad-mesonephros (AGM) region
Implementation Method 2
increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and/or GTPase IMAP Family Member 6 (Gimap6) in the cells under conditions sufficient for stimulating formation of HSCs
Data Source
AI summary
In some aspects and embodiments, the invention provides methods for making hematopoietic stem cells, including for HSCT. The method comprises providing a cell population comprising hemogenic endothelial (HE) or endothelial cells, and increasing activity or expression of DNA (cytosine-5-)-methyltransferase 3 beta (Dnmt3b) and/or GTPase IMAP Family Member 6 (Gimap6) in the HE and/or endothelial cells under conditions sufficient for stimulating formation of HSCs.